List of Excipients in Branded Drug ACETAMINOPHEN, ASPIRIN AND CAFFEINE

Generic Drugs Containing ACETAMINOPHEN, ASPIRIN AND CAFFEINE

Company	Ingredient	NDC	Excipient
Safeway Inc	acetaminophen, aspirin and caffeine	21130-681	CARNAUBA WAX
Safeway Inc	acetaminophen, aspirin and caffeine	21130-681	CELLULOSE, MICROCRYSTALLINE
Safeway Inc	acetaminophen, aspirin and caffeine	21130-681	HYDROXYPROPYL CELLULOSE
Safeway Inc	acetaminophen, aspirin and caffeine	21130-681	HYPROMELLOSE 2910
Safeway Inc	acetaminophen, aspirin and caffeine	21130-681	POLYETHYLENE GLYCOL 400
Safeway Inc	acetaminophen, aspirin and caffeine	21130-681	SODIUM STEARYL FUMARATE
Safeway Inc	acetaminophen, aspirin and caffeine	21130-681	TITANIUM DIOXIDE

What are the Most Frequently-Used Excipients in ACETAMINOPHEN, ASPIRIN AND CAFFEINE?

# Of NDCs	Excipient
4	CARNAUBA WAX
4	CELLULOSE, MICROCRYSTALLINE
4	HYDROXYPROPYL CELLULOSE
4	HYPROMELLOSE 2910
4	POLYETHYLENE GLYCOL 400
4	SODIUM STEARYL FUMARATE
4	TITANIUM DIOXIDE

Acetaminophen, Aspirin and Caffeine Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

Acetaminophen, aspirin and caffeine is a mature, low-barrier analgesic combination with established consumer demand and limited composition-patent protection. The strongest commercial opportunities are differentiated dosage forms, faster onset, gastrointestinal tolerability, lower pill burden, improved adherence, and private-label or regional OTC distribution. Excipient selection must address aspirin hydrolysis, acetaminophen dissolution, caffeine taste, tablet robustness, moisture exposure, and dose-uniformity requirements.

The reference strength used in major U.S. products is typically 250 mg acetaminophen, 250 mg aspirin and 65 mg caffeine per caplet. Excedrin Migraine and Excedrin Extra Strength use this formulation profile.[1][2]

What is the regulatory status of acetaminophen, aspirin and caffeine products?

Acetaminophen, aspirin and caffeine products are marketed in the United States as OTC analgesic combinations. The active ingredients have long-established monograph and labeling pathways, but the regulatory route depends on the precise formulation, claims, dosage form, and compliance with the applicable OTC monograph conditions.

Attribute	Typical product profile
Acetaminophen	250 mg per caplet
Aspirin	250 mg per caplet
Caffeine	65 mg per caplet
Common indication	Temporary relief of headache and migraine pain
Dosage form	Tablet, caplet, coated tablet, or powder-filled capsule
U.S. status	OTC product subject to FDA monograph or approved application requirements
Prescription status	Generally nonprescription
Primary regulatory risks	Liver toxicity, gastrointestinal bleeding, caffeine exposure, labeling compliance

FDA labeling requires warnings relating to acetaminophen-associated liver injury, aspirin-related stomach bleeding, and use in children and teenagers with viral illnesses. Product labeling also restricts use with other acetaminophen-containing medicines and cautions against excessive caffeine consumption.[1][3]

The active-ingredient combination does not receive the regulatory exclusivity typically associated with a new chemical entity. A manufacturer can compete through an OTC monograph-compliant product, an approved application, private-label supply, or a formulation with a differentiated delivery profile.

What excipients are used in acetaminophen, aspirin and caffeine tablets?

Commercial products commonly use a combination of fillers, binders, disintegrants, lubricants, glidants, coating agents and colorants. The exact excipient system depends on whether the manufacturer uses wet granulation, dry granulation, direct compression, or a coated-caplet process.

Representative excipient functions are shown below.

Excipient category	Typical candidates	Primary function
Diluent	Microcrystalline cellulose, dibasic calcium phosphate, lactose, mannitol	Tablet mass and compressibility
Binder	Povidone, copovidone, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Coating polymer	Hypromellose, polyvinyl alcohol	Taste masking, handling, appearance
Plasticizer	Polyethylene glycol, propylene glycol	Coating flexibility
Opacifier	Titanium dioxide or alternative pigments	Appearance and light protection
Sweetener or flavor	Sucralose, saccharin, mint or fruit flavor	Palatability, especially in chewables or powders
Moisture-control material	Desiccant packaging, high-barrier blister film	Stability protection

A formulation should avoid unnecessary excipient complexity. Each additional excipient increases qualification, supplier, extractables, compatibility, and change-control burdens.

How should excipients address aspirin and acetaminophen compatibility?

Aspirin is the principal chemical-stability challenge. It can hydrolyze to salicylic acid and acetic acid under elevated moisture and temperature conditions. Acetaminophen also requires protection from oxidation, moisture, and prolonged exposure to unsuitable pH environments.

A practical formulation strategy includes:

1. Use low-moisture excipients and control water activity.
2. Avoid strongly alkaline excipients that may accelerate aspirin hydrolysis.
3. Minimize aqueous processing unless stability data support wet granulation.
4. Evaluate excipient peroxide levels, particularly for cellulose-based materials and polymeric binders.
5. Use high-barrier packaging for humidity-sensitive presentations.
6. Control lubricant concentration and blending time to preserve dissolution.
7. Test aspirin hydrolysis, acetaminophen degradation, caffeine assay, dissolution, hardness, friability and disintegration together.

Direct compression is attractive because it reduces water and heat exposure. It requires powders with compatible particle-size distributions and adequate flow. Dry granulation can improve blend uniformity and tablet strength while retaining a low-moisture process. Wet granulation may improve compressibility but creates a higher aspirin-stability burden.

What formulation strategy is best for commercial launch?

The best launch platform depends on the target price, indication, and claimed performance.

Standard immediate-release caplet

This is the lowest-risk option. It can use a conventional filler-disintegrant-lubricant system with film coating and moisture-protective packaging. The commercial advantage is cost and manufacturing simplicity, but the product is difficult to distinguish from established generics.

A representative platform could use microcrystalline cellulose or dibasic calcium phosphate, crospovidone, colloidal silicon dioxide, magnesium stearate and a hypromellose film coat. The formulation should target rapid disintegration without creating excessive friability or capping.

Fast-dissolving or rapid-disintegration tablet

A rapid-disintegration product can support claims or positioning around convenient use and early dissolution, subject to substantiation and compliant labeling. Crospovidone, low-substituted hydroxypropyl cellulose and porous excipient systems can improve water penetration.

The formulation must prevent premature softening during storage. Packaging is critical because high-porosity tablets absorb moisture more readily.

Chewable tablet

Chewables create a clear excipient opportunity because caffeine and aspirin can produce strong bitterness and irritation. Taste masking may require polymer coating, ion-exchange technology, flavor systems, sweeteners and a controlled particle-size distribution.

A chewable version can target consumers who have difficulty swallowing tablets, but aspirin taste and local gastric irritation remain formulation constraints. The active dose also creates a large tablet mass, which may require two units per dose or a larger-format tablet.

Powder or effervescent dosage form

Powdered and effervescent products can differentiate through rapid dispersion and perceived onset. They require strict control of moisture, acid-base compatibility, hygroscopicity and packaging seal integrity.

Effervescent systems may create chemical-stability challenges for aspirin and acetaminophen. They also increase manufacturing and packaging cost. Sachets, stick packs and unit-dose pouches can support travel and convenience positioning.

Liquid-filled or multiparticulate capsule

A liquid or multiparticulate system may improve dissolution but has a higher development burden. Aspirin stability in liquid environments is a major concern, making a conventional liquid formulation less attractive than dry multiparticulates or coated granules.

What formulation patents protect acetaminophen, aspirin and caffeine products?

The active-ingredient combination is old and generally offers little opportunity for a new composition-of-matter patent. Commercial protection is more likely to arise from:

• Taste-masked particles or coated active ingredients.
• Modified-release or pulsatile-release systems.
• Effervescent compositions.
• Low-moisture manufacturing processes.
• Specific tablet architecture or multilayer structures.
• Packaging systems that improve stability.
• Narrow dissolution profiles tied to a clinically relevant performance claim.
• Pediatric, geriatric or swallowability-focused dosage forms.
• Combination products with additional active ingredients.

Historical Excedrin-related patent protection has not created a durable barrier comparable to the patent estate around a modern prescription drug. The principal commercial assets are brand recognition, trademarks, distribution, retailer placement, product reviews and consumer familiarity.

A new patent position would need to claim a technically meaningful improvement rather than merely restating the known active combination. Stronger claims would generally require comparative data showing improved stability, dissolution, tolerability, onset, adherence or manufacturing efficiency.

When does acetaminophen, aspirin and caffeine lose exclusivity?

The combination has already lost practical exclusivity at the active-ingredient level. Generic and store-brand products have competed for years.

Protection type	Commercial position
Active ingredients	Generic and widely available
Combination concept	Mature and broadly replicable
Brand name	Protected by trademark, not patent exclusivity
Trade dress	Potentially enforceable against confusingly similar packaging
Formulation patent	Depends on the specific product and claim scope
Method-of-use patent	Limited value for conventional headache and migraine claims
Manufacturing know-how	Potentially valuable but generally confidential
Distribution agreements	Can create temporary channel advantages

The principal generic-entry risk is therefore immediate substitution and retail price competition, not a future patent cliff. A branded product must justify its premium through recognition, convenience, differentiated packaging, dosage form, or evidence-supported product performance.

What is the Orange Book status of these products?

The Orange Book primarily lists approved prescription drug products and does not function as a complete patent registry for ordinary OTC monograph products. A monograph-compliant OTC product may not have an Orange Book patent listing comparable to an NDA product.

For an approved NDA product, listed patents may include formulation, method-of-use or drug-delivery claims. For a standard OTC product, commercial competitors should review FDA monographs, approved applications, DailyMed labeling, trademark records, patent databases and product-specific regulatory filings rather than rely only on Orange Book data.[4][5]

Paragraph IV litigation is not the normal market-entry pathway for a conventional OTC monograph-compliant acetaminophen, aspirin and caffeine product. Paragraph IV risk becomes relevant if a competitor seeks approval through an ANDA or challenges patents associated with an approved NDA product.

Which companies compete in the acetaminophen, aspirin and caffeine market?

The market includes branded, generic, private-label and retailer-owned products.

Competitor group	Examples of commercial strategy
Branded innovator	Excedrin Migraine, Excedrin Extra Strength
Generic manufacturers	Low-cost equivalent-strength caplets and tablets
Retail pharmacy brands	Private-label versions positioned below branded pricing
Club and mass retailers	Large-count bottles and multipacks
E-commerce sellers	Search-driven products, subscription purchasing and specialty packaging
Contract manufacturers	OTC platform manufacturing for multiple labels

The branded leader benefits from name recognition and consumer association with migraine relief. Generic competitors usually compete on count size and price. A new entrant needs either a lower delivered cost or a product attribute that consumers and retailers can understand quickly.

What are the strongest commercial opportunities?

Private-label and contract manufacturing

Private-label supply is the most accessible opportunity. Retailers can launch equivalent-strength products with modest formulation work if the product complies with the applicable regulatory pathway and labeling requirements.

The main value drivers are:

• Reliable API sourcing.
• Low-cost direct compression.
• High-throughput caplet manufacturing.
• Flexible bottle, blister and pouch packaging.
• Retailer-specific count sizes.
• Stable supply during OTC shortages or demand surges.

Migraine-focused dosage forms

A migraine-positioned product can differentiate through rapid disintegration, portability, smaller tablets, blister packaging and clear caffeine disclosure. The product must avoid unsupported claims that imply superiority over approved or established products.

Caffeine-controlled products

Caffeine is both an active ingredient and a consumer concern. A product can be positioned around transparent caffeine content, reduced stimulant exposure, or a standard-strength dose that is easy to calculate alongside coffee and energy drinks.

Reducing caffeine may alter the regulatory status or require a different product rationale. A lower-caffeine formulation also loses direct equivalence to the established 65 mg-per-unit profile.

Gastrointestinal-tolerability strategy

Aspirin creates a barrier to consumers with gastrointestinal sensitivity. Opportunities include delayed-release aspirin particles, protective coatings, or dosing presentations designed to reduce local irritation. These approaches carry development risk because delayed release may conflict with rapid-relief positioning and may alter the safety profile.

Travel and single-dose packaging

Unit-dose blister packs, sachets and stick packs can support portability, adherence and controlled dosing. Packaging is also a potential source of patentable differentiation if it contributes to stability or dosing accuracy.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate rather than high. The primary technical risks are blend segregation, tablet weight variation, aspirin degradation, coating defects and dissolution drift.

The principal intellectual-property barriers are:

1. Trademark restrictions around names such as Excedrin.
2. Trade-dress restrictions involving similar colors, layouts or product presentation.
3. Active formulation patents for specific modified-release or taste-masked products.
4. Process patents covering specialized granulation or coating methods.
5. Contract manufacturing exclusivity and supply agreements.
6. Regulatory data or application-specific protections where an NDA is involved.

A standard immediate-release generic has limited freedom-to-operate risk after review of current patents and trademarks. A differentiated product using coated particles, multilayer tablets or modified release requires a more extensive patent search.

How does this combination compare with competing analgesic products?

Product type	Main advantage	Main commercial weakness
Acetaminophen alone	Lower gastrointestinal risk than aspirin for many users	Liver-toxicity concerns at excessive doses; may provide weaker migraine positioning
Ibuprofen	Anti-inflammatory activity and strong OTC recognition	Gastrointestinal, renal and cardiovascular warnings
Naproxen	Longer duration	Slower perceived onset and NSAID-related risks
Aspirin, acetaminophen and caffeine	Familiar migraine combination and strong consumer recognition	Higher warning burden and caffeine exposure
Acetaminophen and caffeine	Avoids aspirin-related bleeding concerns	May have less established migraine brand equity
Non-oral migraine products	Potentially useful for nausea or swallowing difficulty	Higher development and manufacturing cost

The three-active combination is commercially strongest where consumers value a familiar migraine or severe-headache product. It is less attractive for daily-use positioning because of cumulative acetaminophen, aspirin and caffeine exposure.

What litigation and settlement issues affect market entry?

A conventional OTC product faces limited Paragraph IV litigation exposure unless it is tied to an approved NDA with active listed patents. More relevant disputes include:

• Trademark infringement.
• Trade-dress imitation.
• False or misleading comparative advertising.
• Packaging similarity.
• Unauthorized private-label distribution.
• Contract manufacturing and supply disputes.
• Regulatory challenges to labeling or claims.

Settlement agreements are less likely to control entry for a simple OTC monograph product than for a patented prescription medicine. Where a branded product has an NDA-linked formulation patent, settlement terms may include launch dates, authorized-generic arrangements or restrictions on formulation changes.

What is the revenue exposure for branded products?

Product-specific revenue for acetaminophen, aspirin and caffeine combinations is not generally reported separately by public companies. Revenue exposure is usually embedded within broader OTC analgesic portfolios.

Commercial sensitivity is highest in:

• Migraine and headache categories.
• Mass retail and pharmacy channels.
• Private-label substitution.
• Promotional pricing periods.
• Retailer shelf resets.
• Consumer switching during inflationary periods.
• Supply disruptions involving acetaminophen, aspirin or caffeine APIs.

For a branded manufacturer, the combination can generate attractive gross margins because the active ingredients are inexpensive relative to the finished-product price. The cost base is driven more by packaging, quality systems, distribution, marketing and retailer terms than by API value.

Key Takeaways

• Acetaminophen, aspirin and caffeine is a mature OTC combination with no practical active-ingredient exclusivity.
• The common reference strength is 250 mg acetaminophen, 250 mg aspirin and 65 mg caffeine per caplet.
• Aspirin hydrolysis and moisture control are the central formulation challenges.
• Direct compression and dry granulation are generally more attractive than aqueous wet granulation for stability-sensitive products.
• Excipients should be selected for rapid disintegration, low moisture, peroxide control, powder flow and tablet robustness.
• The best commercial opportunities are private-label supply, rapid-disintegration products, travel packaging, chewables, powders and differentiated migraine presentations.
• Patent value is more likely in taste masking, modified release, packaging, process controls and stability improvements than in the active combination itself.
• Orange Book and Paragraph IV analysis is relevant mainly where an approved NDA or active formulation patents are involved.
• Brand, trademark, trade dress, retail distribution and consumer recognition are stronger barriers than composition patents.
• A new product must compete on price, convenience, tolerability, packaging or measurable performance.

FAQs

Can acetaminophen, aspirin and caffeine be formulated as a liquid?

Yes, but aspirin stability makes a liquid product technically difficult. Dry powders, coated granules or reconstitutable systems are generally more practical than an aqueous liquid.

Which excipient best improves tablet disintegration?

Crospovidone and croscarmellose sodium are common choices. Selection depends on compression force, tablet porosity, moisture exposure and the target dissolution profile.

Is an enteric-coated version commercially attractive?

It can reduce direct gastric exposure from aspirin, but delayed release may conflict with rapid-relief positioning. The product would require comparative stability, dissolution and tolerability data.

Can a company patent a new acetaminophen, aspirin and caffeine product?

Yes, but a patent would generally need to claim a novel formulation, delivery system, manufacturing process, packaging configuration or demonstrated performance advantage. The basic active combination is not a strong patent subject.

Is caffeine necessary in a migraine combination product?

Caffeine is not necessary for every analgesic product, but it is part of the established three-ingredient combination and supports a differentiated migraine-positioning strategy. Removing or materially reducing it may change the product’s equivalence, labeling and commercial profile.

References

1. DailyMed. (n.d.). Excedrin Migraine acetaminophen, aspirin, and caffeine tablet, film coated: Drug label. U.S. National Library of Medicine.
2. DailyMed. (n.d.). Excedrin Extra Strength acetaminophen, aspirin, and caffeine tablet, film coated: Drug label. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Acetaminophen information. https://www.fda.gov/drugs/information-drug-class/acetaminophen-information
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
5. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.accessdata.fda.gov/scripts/cder/omuf/strand.cfm?StartRow=1&frame=1